Roche chops TNBC programs following PhIII flops, further dimming the spotlight on Array drug
One of Roche’s spotlight PhIII cancer drug hopefuls is losing more of its aura.
All but pulling the plug on the ipatasertib program in triple-negative breast cancer, Roche disclosed in a quarterly filing that it’s killed two Phase III programs: IPATunity-130, which was testing the ATK blocker plus chemotherapy in frontline TNBC or hormone receptor-positive breast cancer, and IPATunity-170, which focuses on a combination of ipatasertib, Tecentriq and taxane in frontline TNBC.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.